Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Afluria Quadrivalent Market Size Forecast: How Big Could The Market Get By 2030?#_x000D_
The historical expansion was propelled by the constraints of trivalent influenza vaccines, repeated multi-strain flu outbreaks, an increase in hospitalization rates due to influenza, pre-existing immunization schedules, and government-funded vaccination programs._x000D_
_x000D_
Growth during the projected timeframe is primarily driven by the demand for more comprehensive strain protection, a rise in healthcare professional immunizations, the expansion of childhood vaccination initiatives, increased government purchasing, and novel approaches in vaccine delivery formats. Concurrently, significant trends anticipated for the forecast period include the increasing adoption of quadrivalent influenza vaccines, enhanced defense against multiple flu strains, higher vaccination rates among high-risk populations, the proliferation of governmental immunization efforts, and breakthroughs in vaccine formulation technologies._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Afluria Quadrivalent Market Industry Drivers: What’s Behind The Revenue Growth?#_x000D_
The rising occurrence of influenza is anticipated to fuel expansion in the afluria quadrivalent market in the future. Influenza, a transmissible respiratory sickness caused by viruses, can result in symptoms ranging from mild to severe, such as fever, cough, and body aches. This rise in influenza cases is influenced by factors like the virus’s yearly mutation, prevailing seasonal conditions, and insufficient vaccination coverage in specific communities. Afluria Quadrivalent is vital in addressing the growing prevalence of influenza by offering defense against four common flu strains, thereby lowering infection risks and lessening the severity of seasonal epidemics. For example, in November 2024, the UK Health Security Agency, a UK-based government agency, reported an increase in influenza positivity rates in week 46, with a weekly average of 3.9%, an increase from 3.3% the week prior. Among those aged 5 to 14, the highest positivity rates were recorded, reaching a weekly average of 11.6%, up from 8.8% in week 45. Consequently, the increasing prevalence of influenza will contribute to the growth of the afluria quadrivalent market. Higher birth rates are projected to stimulate the expansion of the afluria quadrivalent market moving forward. This rise in birth rates stems from several elements, including advancements in healthcare, governmental encouragement, and evolving social perspectives. A greater number of births results in a larger demographic of children who require vaccinations. With rising birth rates, healthcare infrastructures must vaccinate more children to guard against influenza, thereby elevating the demand for vaccines such as Afluria Quadrivalent. For example, in October 2024, the Australian Bureau of Statistics, an Australia-based government agency, reported 24,737 Aboriginal and Torres Strait Islander births registered in 2023, representing an increase of 349 infants compared to 2022. Therefore, increasing birth rates are fostering the growth of the afluria quadrivalent market._x000D_
_x000D_
#Afluria Quadrivalent Market Segment Outlook: Which Categories Are Growing Fastest?#_x000D_
The afluria quadrivalent market covered in this report is segmented – _x000D_
_x000D_
1) By Clinical Indication: Seasonal Influenza Prophylaxis, High-Risk Population Immunization, Pediatric Influenza Prophylaxis, Healthcare Worker Immunization_x000D_
2) By Route Of Administration: Injection, Nasal Spray_x000D_
3) By Age Group: Adults, Geriatric, Pediatrics_x000D_
4) By Distribution Channel: Hospital And Retail Pharmacies, Government Suppliers, Other Channels_x000D_
5) By End-User: Hospitals, Public, Private, Clinics, Other End-Users_x000D_
_x000D_
_x000D_
_x000D_
_x000D_
#Afluria Quadrivalent Market Leading Companies And Competitive Benchmarking#_x000D_
Major companies operating in the afluria quadrivalent market are Seqirus Inc. _x000D_
_x000D_
#View The Full Afluria Quadrivalent Market Report:#_x000D_
_x000D_
#Afluria Quadrivalent Market Regional Distribution: Which Areas Power Market Growth?#_x000D_
North America was the largest region in the afluria quadrivalent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afluria quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model